Drug firms looking to ramp-up production with continuous processes must think beyond the reactor and ensure the technologies used downstream can also manage sustained 24/7 manufacturing. Continuous ...
Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback